Cytokinetics Starts Heart-Failure Phase IIa
This article was originally published in The Pink Sheet Daily
Executive Summary
With its second study, the firm “turns a corner” on enrollment problems.
You may also be interested in...
Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position
Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.
Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position
Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.
Cytokinetics’ First Phase IIa Data Strong For Heart Failure Drug
Success takes the firm closer to Amgen payday.